Lumora Secures New India Patent for its BART portfolio Technologies

Cambridgeshire, UK, 30 September 2014 ... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has secured a further patent for its growing portfolio of BART-related (Bioluminescent Assay in Real Time) technologies with the granting of its second BART patent in India. 

BART is a proprietary real-time molecular system that integrates with isothermal processes for the detection of DNA and RNA. It holds a significant number of advantages compared to traditional methods as it is less expensive, easier to use and produces highly accurate results. 

Lumora has developed a number of biochemical approaches to utilise bioluminescence for use in molecular diagnostics.  This latest patent grant is part of a supporting family of BART patents that broaden the ways in which BART can be implemented.

Laurence Tisi, CEO of Lumora, said: “BART is an incredibly strong technology, and provides a cost effective, easy to use platform for the detection of DNA and RNA. Its ease of use and lower cost, means it is ideal for markets where there can be significant barriers to adopting costly, and complicated technologies which rely on a high level of infrastructure to function effectively.  The granting of additional patents in the BART family emphasises the robustness of our IP position”

Hayden Jeffreys, Commercial Director at Lumora, added: “The granting of this patent is a significant step in Lumora’s global commercialisation strategy. With this new patent we are now further consolidating real-time bioluminescence as a uniquely Lumora technology. Combined with the recent launch of our range of sample preparation technologies, Lumora now has a strong range of sample preparation and assay technologies which can be used in a range of environments.”

The granting of the patent follows a number of significant developments for Lumora over the last couple of years. This includes a series of deals with commercial partners which is seeing BART used widely as the basis for molecular testing, while more recently Lumora announced the development of a series of new approaches in sample preparation.

-ends-

For further information please contact:

Tony Stephenson, Director

Exitus Communications 

Tel: +44 (0)7899 796655

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.  

Notes to Editors: 

About Lumora

Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non-clinical or industrial markets. Lumora's easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is active in commercialising its technology and our development and commercialisation partners include international biotechnology, clinical diagnostic and industrial microbiology companies.


Lumora's corporate office is based just outside of Cambridge, England. The Company's investors include; Tate Lyle Ventures LP, Cambridge Enterprise (University of Cambridge), and Catapult Venture Managers Ltd.
www.lumora.co.uk